Infinity Starts Chondrosarcoma Drug Trial

Infinity Pharmaceuticals announced the initiation of a randomized, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of IPI-926.

Infinity Pharmaceuticals has launched a Phase II clinical trial to evaluate IPI-926 as a treatment for patients with metastatic or locally advanced inoperable chondrosarcoma, a rare bone cancer. The randomised, double-blind trial is designed to evaluate the safety and efficacy of IPI-926 compared to placebo, and will enrol more than 100 patients worldwide.

IPI-926 is a novel, oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway.

The primary endpoint of the trial is progression-free survival, while secondary endpoints include time-to-progression, overall survival, overall response rate and response duration.